iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/24662192/
Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014;4(3):337-44.
doi: 10.3233/JPD-140364.

Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease

Iciar Aviles-Olmos  1 , John Dickson  2 , Zinovia Kefalopoulou  1 , Atbin Djamshidian  3 , Joshua Kahan  1 , Peter Ell  2 , Peter Whitton  4 , Richard Wyse  5 , Tom Isaacs  5 , Andrew Lees  3 , Patricia Limousin  1 , Thomas Foltynie  1
Affiliations
Randomized Controlled Trial

Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease

Iciar Aviles-Olmos et al. J Parkinsons Dis. 2014.

Abstract

Background: Data from an open label randomised controlled trial have suggested possible advantages on both motor and non-motor measures in patients with Parkinson's disease following 12 months exposure to exenatide.

Objective: Continued follow up of these same patients was performed to investigate whether these possible advantages persisted in the prolonged absence of this medication.

Methods: All participants from an open label, randomised controlled trial of exenatide as a treatment for Parkinson's disease, were invited for a further follow up assessment at the UCL Institute of Neurology. This visit included all 20 individuals who had previously completed twelve months exposure to exenatide 10ug bd and the 24 individuals who had acted as randomised controls. Motor severity of PD was compared after overnight withdrawal of conventional PD medication using blinded video assessment of the MDS-UPDRS, together with several non-motor tests. This assessment was thus 24 months after their original baseline visit, i.e. 12 months after cessation of exenatide.

Results: Compared to the control group of patients, patients previously exposed to exenatide had an advantage of 5.6 points (95% CI, 2.2-9.0; p = 0.002) using blinded video rating of the MDS-UPDRS part 3 motor subscale. There was also a difference of 5.3 points; (95% CI, 9.3-1.4; p = 0.006) between the 2 groups on the Mattis Dementia Rating scale.

Conclusions: While these data must still not be interpreted as evidence of neuroprotection, they nevertheless provide strong encouragement for the further study of this drug as a potential disease modifying agent in Parkinson's disease.

Keywords: Parkinson's disease; UPDRS; clinical trial; diabetes mellitus; disease modifying treatment; exenatide.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types